Literature DB >> 22844653

Oxadiazole 2-oxides are toxic to the human hookworm, Ancylostoma ceylanicum, however glutathione reductase is not the primary target.

R S Treger1, A G Cook, G Rai, D J Maloney, A Simeonov, A Jadhav, C J Thomas, D L Williams, M Cappello, J J Vermeire.   

Abstract

Hookworm disease, characterized by severe anemia and cognitive and growth delays, currently affects an estimated 740 million people worldwide. Despite the prevalence of this parasitic disease, few effective drug therapies are in use today, and the heavy reliance upon benzimidazoles highlights the need for the development of novel chemotherapies. Recent work with the trematode parasite Schistosoma mansoni has identified oxadiazole 2-oxides as effective antischistosomal compounds that function by targeting and inhibiting the antioxidant enzyme, thioredoxin glutathione reductase. In this study, a related enzyme, glutathione reductase, from the human hookworm Ancylostoma ceylanicum was identified and characterized, and its in vitro activity in the presence of the oxadiazole 2-oxides was analyzed. Ex vivo worm killing assays were also conducted to establish the relationship between a given compound's effect upon worm survival and inhibition of recombinant glutathione reductase (rAceGR). Finally, the in vivo anthelminthic efficacy of furoxan (Fx) was assessed in the hamster model of hookworm infection. The predicted amino acid sequence of AceGR contained a prototypical glutathione reductase active site sequence, but no thioredoxin reductase consensus sequences, suggesting that the glutathione and thioredoxin pathways of A. ceylanicum are distinct. Although ten of the forty-two oxadiazole 2-oxides tested inhibited rAceGR activity by at least fifty percent, and fifteen compounds were toxic to parasites ex vivo, little overlap existed between these two results. We therefore suggest that AceGR is not the primary target of the oxadiazole 2-oxides in effecting parasite death. Lastly, oral treatment of A. ceylanicuminfected hamsters with furoxan resulted in significantly improved weight gains and reduced intestinal worm burdens compared to vehicle treated controls, supporting continued development of this molecule as a novel anthelminthic.

Entities:  

Year:  2012        PMID: 22844653      PMCID: PMC3404738          DOI: 10.1016/j.ijpddr.2012.05.001

Source DB:  PubMed          Journal:  Int J Parasitol Drugs Drug Resist        ISSN: 2211-3207            Impact factor:   4.077


  27 in total

1.  Mitigation of hookworm disease by immunization with soluble extracts of Ancylostoma ceylanicum.

Authors:  R D Bungiro; J Greene; E Kruglov; M Cappello
Journal:  J Infect Dis       Date:  2001-04-10       Impact factor: 5.226

2.  Mammalian thioredoxin reductase: oxidation of the C-terminal cysteine/selenocysteine active site forms a thioselenide, and replacement of selenium with sulfur markedly reduces catalytic activity.

Authors:  S R Lee; S Bar-Noy; J Kwon; R L Levine; T C Stadtman; S G Rhee
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

Review 3.  Developing vaccines to combat hookworm infection and intestinal schistosomiasis.

Authors:  Peter J Hotez; Jeffrey M Bethony; David J Diemert; Mark Pearson; Alex Loukas
Journal:  Nat Rev Microbiol       Date:  2010-11       Impact factor: 60.633

Review 4.  Will technology provide solutions for drug resistance in veterinary helminths?

Authors:  Georg von Samson-Himmelstjerna; William Blackhall
Journal:  Vet Parasitol       Date:  2005-09-30       Impact factor: 2.738

Review 5.  The drugs we have and the drugs we need against major helminth infections.

Authors:  Jennifer Keiser; Jürg Utzinger
Journal:  Adv Parasitol       Date:  2010       Impact factor: 3.870

6.  Three-dimensional structure of a mammalian thioredoxin reductase: implications for mechanism and evolution of a selenocysteine-dependent enzyme.

Authors:  T Sandalova; L Zhong; Y Lindqvist; A Holmgren; G Schneider
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-31       Impact factor: 11.205

7.  Twenty-first century progress toward the global control of human hookworm infection.

Authors:  Richard Bungiro; Michael Cappello
Journal:  Curr Infect Dis Rep       Date:  2011-06       Impact factor: 3.725

8.  A 1,536-well-based kinetic HTS assay for inhibitors of Schistosoma mansoni thioredoxin glutathione reductase.

Authors:  Wendy A Lea; Ajit Jadhav; Ganesha Rai; Ahmed A Sayed; Cynthia L Cass; James Inglese; David L Williams; Christopher P Austin; Anton Simeonov
Journal:  Assay Drug Dev Technol       Date:  2008-08       Impact factor: 1.738

9.  Thioredoxin and glutathione systems differ in parasitic and free-living platyhelminths.

Authors:  Lucía Otero; Mariana Bonilla; Anna V Protasio; Cecilia Fernández; Vadim N Gladyshev; Gustavo Salinas
Journal:  BMC Genomics       Date:  2010-04-13       Impact factor: 3.969

Review 10.  Anthelmintic resistance.

Authors:  R Prichard
Journal:  Vet Parasitol       Date:  1994-08       Impact factor: 2.738

View more
  3 in total

1.  In vitro screening of compounds against laboratory and field isolates of human hookworm reveals quantitative differences in anthelmintic susceptibility.

Authors:  Rebecca S Treger; Joseph Otchere; Martin F Keil; Josephine E Quagraine; Ganesha Rai; Bryan T Mott; Debbie L Humphries; Michael Wilson; Michael Cappello; Jon J Vermeire
Journal:  Am J Trop Med Hyg       Date:  2013-12-02       Impact factor: 2.345

2.  A furoxan-amodiaquine hybrid as a potential therapeutic for three parasitic diseases().

Authors:  Bryan T Mott; Ken Chih-Chien Cheng; Rajarshi Guha; Valerie P Kommer; David L Williams; Jon J Vermeire; Michael Cappello; David J Maloney; Ganesha Rai; Ajit Jadhav; Anton Simeonov; James Inglese; Gary H Posner; Craig J Thomas
Journal:  Medchemcomm       Date:  2012-12       Impact factor: 3.597

3.  Oxadiazole-2-oxides may have other functional targets, in addition to SjTGR, through which they cause mortality in Schistosoma japonicum.

Authors:  Li-Jun Song; Huan Luo; Wen-Hua Fan; Gu-Ping Wang; Xu-Ren Yin; Shuang Shen; Jie Wang; Yi Jin; Wei Zhang; Hong Gao; Qian Liu; Wen-Long Wang; Bainian Feng; Chuan-Xin Yu
Journal:  Parasit Vectors       Date:  2016-01-20       Impact factor: 3.876

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.